Brazil: 2 deaths, dozens of cases with warning signs, prompts temporary discontinuation of the current Butantan-DV vaccine
Brazil has temporarily suspended the use of the Butantan-DV dengue vaccine following two deaths and 42 reports of adverse reactions. Health officials emphasize that this is a precautionary measure while they investigate a potential causal link.
Why it matters
The suspension of a vaccination program impacts public health strategy and highlights the importance of post-market surveillance in medical safety.
Robert Herriman Jun 09, 2026 Share In a follow-up to a report from February, the Brazil Ministry of Health announced Monday the temporary discontinuation of the current Butantan-DV vaccination strategy against dengue.
The article balances the report of adverse events with official statements regarding the vaccine's prior safety testing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in